Lixte Net Invested Capital vs Cash And Short Term Investments Analysis
LIXT Stock | USD 2.67 0.10 3.61% |
Lixte Biotechnology financial indicator trend analysis is infinitely more than just investigating Lixte Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lixte Biotechnology is a good investment. Please check the relationship between Lixte Biotechnology Net Invested Capital and its Cash And Short Term Investments accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
Net Invested Capital vs Cash And Short Term Investments
Net Invested Capital vs Cash And Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lixte Biotechnology Net Invested Capital account and Cash And Short Term Investments. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Lixte Biotechnology's Net Invested Capital and Cash And Short Term Investments is 0.98. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Lixte Biotechnology Holdings, assuming nothing else is changed. The correlation between historical values of Lixte Biotechnology's Net Invested Capital and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of Lixte Biotechnology Holdings are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Net Invested Capital i.e., Lixte Biotechnology's Net Invested Capital and Cash And Short Term Investments go up and down completely randomly.
Correlation Coefficient | 0.98 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Lixte Biotechnology balance sheet. This account contains Lixte Biotechnology investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Lixte Biotechnology Holdings fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Most indicators from Lixte Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lixte Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. Issuance Of Capital Stock is likely to gain to about 3.9 M in 2024, whereas Selling General Administrative is likely to drop 3,983 in 2024.
Lixte Biotechnology fundamental ratios Correlations
Click cells to compare fundamentals
Lixte Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lixte Biotechnology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.7M | 5.2M | 5.1M | 5.6M | 4.3M | 2.2M | |
Other Current Liab | 237.9K | 10.5K | 302.9K | 394.8K | 313.9K | 171.6K | |
Total Current Liabilities | 237.9K | 216.5K | 302.9K | 394.8K | 313.9K | 290.7K | |
Total Stockholder Equity | 2.4M | 5.0M | 4.8M | 5.2M | 4.0M | 4.2M | |
Net Debt | (2.6M) | (5.1M) | (4.8M) | (5.4M) | (4.2M) | (4.0M) | |
Retained Earnings | (27.1M) | (30.4M) | (37.1M) | (43.4M) | (48.5M) | (46.1M) | |
Cash | 2.6M | 5.1M | 4.8M | 5.4M | 4.2M | 4.4M | |
Cash And Short Term Investments | 2.6M | 5.1M | 4.8M | 5.4M | 4.2M | 4.4M | |
Common Stock Shares Outstanding | 1.1M | 1.1M | 1.3M | 158.2K | 1.9M | 1.8M | |
Liabilities And Stockholders Equity | 2.7M | 5.2M | 5.1M | 5.6M | 4.3M | 2.2M | |
Other Stockholder Equity | 26.0M | 31.9M | 38.4M | 45.1M | 49.0M | 51.4M | |
Total Liab | 237.9K | 216.5K | 302.9K | 394.8K | 313.9K | 290.7K | |
Total Current Assets | 2.7M | 5.2M | 5.1M | 5.6M | 4.2M | 2.2M | |
Accounts Payable | 143.5K | 190.3K | 226.0K | 229.8K | 156.8K | 169.4K | |
Other Current Assets | 58.8K | 15K | 10.2K | 10.4K | 27.1K | 54.0K | |
Short Term Debt | (210.9K) | (237.9K) | (302.9K) | (394.8K) | (313.9K) | (298.2K) | |
Current Deferred Revenue | 94.3K | 15.8K | 77.0K | 165.0K | 157.1K | 81.5K | |
Net Tangible Assets | 625.8K | (1.1M) | 1.5M | 1.3M | 1.5M | 1.6M | |
Net Invested Capital | (1.1M) | 1.5M | 1.3M | 1.7M | 494.8K | 317K | |
Net Working Capital | 2.4M | 5.0M | 4.8M | 5.2M | 4.0M | 4.2M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lixte Biotechnology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lixte Biotechnology's short interest history, or implied volatility extrapolated from Lixte Biotechnology options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Lixte Stock analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Return On Assets (0.64) | Return On Equity (1.11) |
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.